QUICK ANSWER
An M-spike (monoclonal spike or M-protein) is a sharp protein peak detected on serum protein electrophoresis (SPEP), indicating an abnormal accumulation of a single type of antibody (immunoglobulin) produced by clonal plasma cells.
Normal result: "Not observed" or "Not detected." Any detectable M-spike is technically abnormal, but the clinical significance depends entirely on the level.
A small M-spike does not mean you have cancer. The vast majority of people with an M-spike have MGUS (Monoclonal Gammopathy of Undetermined Significance) — a benign condition that requires monitoring but not treatment. Long-term studies suggest most people with MGUS never progress to myeloma; the average annual risk is approximately 1% per year.
Key takeaway: An M-spike is a finding that requires evaluation, not a diagnosis. The most important questions are: What is the level? Is it stable or rising? Are there symptoms? Small, stable M-spikes under close monitoring are the most common scenario — and most people with one will never develop myeloma.
WHAT DOES MY M-SPIKE VALUE MEAN?
The level of the M-spike (measured in g/dL) is the primary factor determining clinical significance:
| M-spike level | Interpretation | Typical clinical action |
|---|---|---|
| Not observed / Not detected | Normal — no monoclonal protein found | No action needed |
| Faint band / < 0.3 g/dL | Very low — may represent trace MGUS or assay noise | Confirm with immunofixation; repeat SPEP in 3–6 months |
| 0.3–0.5 g/dL | Low positive — consistent with low-risk MGUS | Immunofixation to characterise; annual monitoring |
| 0.5–1.0 g/dL | Low-moderate — consistent with MGUS | Annual monitoring with full MGUS workup |
| 1.0–3.0 g/dL | Moderate — consistent with MGUS or smoldering myeloma | Every 3–6 month monitoring; full haematology evaluation |
| ≥ 3.0 g/dL | High — meets SMM threshold; active evaluation warranted | Haematology referral; bone marrow biopsy consideration |
| ≥ 3.0 g/dL + CRAB symptoms | Possible active multiple myeloma | Urgent haematology referral |
CRAB symptoms: Calcium elevation, Renal dysfunction, Anaemia, Bone lesions
⚠️ Contact your clinician promptly if:
- The M-spike is rising between serial tests (increase ≥ 0.5 g/dL over 6 months)
- The M-spike is ≥ 3.0 g/dL
- Any M-spike appears alongside: anaemia, kidney dysfunction, elevated calcium, bone pain, unexplained weight loss, recurrent infections, or significant fatigue
A low M-spike value with any of these features can be more concerning than the number alone suggests. The combination of symptoms and lab findings — not the M-spike level in isolation — determines urgency.
IS 0.3, 0.4, 0.5, OR 0.6 g/dL A HIGH M-SPIKE?
This is the most common question from people who receive an M-spike result.
0.3 g/dL: Low positive. This level is consistent with low-risk MGUS. It is not considered "high" in the sense of indicating active myeloma. Most clinicians would order immunofixation to characterise the protein type and schedule annual monitoring.
0.4 g/dL: Low positive. Same interpretation as 0.3 g/dL — consistent with low-risk MGUS. Annual monitoring is the standard approach. This value does not indicate multiple myeloma.
0.5 g/dL: Low-moderate. Still within the MGUS range. No single threshold at 0.5 g/dL changes clinical management dramatically, but values approaching 1.0 g/dL are monitored more carefully.
0.6–0.9 g/dL: Low-moderate. Consistent with MGUS. Annual haematology review is standard. The key question at this level is whether the value is stable or rising over serial tests.
1.0 g/dL: Moderate. Still typically consistent with MGUS, but at 1.0 g/dL and above, haematologists may recommend more frequent monitoring (every 6 months) and a more thorough baseline evaluation including bone marrow biopsy consideration.
The most important number is not the absolute value but the trend. A stable 0.8 g/dL observed over 5 years is much less concerning than a 0.4 g/dL that has doubled in 6 months.
Equally important: a low M-spike with abnormal free light chains, kidney changes, anaemia, or bone pain can be more clinically significant than the number alone suggests. Values should never be interpreted in isolation from symptoms and the rest of the blood panel.
WHAT DOES "M-SPIKE NOT OBSERVED" OR "NOT DETECTED" MEAN?
"M-spike not observed," "no M-spike detected," "no restricted band seen," or "no monoclonal protein detected" all mean the same thing: no abnormal monoclonal protein was found. This is a normal result.
Related phrases you may see on a lab report:
- "No M-spike detected" — normal
- "M-spike not observed" — normal
- "M-spike not seen" — normal
- "No restricted band (M-spike) seen" — normal (LabCorp language)
- "No monoclonal protein is apparent" — normal
- "M component not present" — normal
If you received one of these results, no monoclonal protein was identified. No action is required for the M-spike result alone.
WHAT DOES "FAINT RESTRICTED BAND (M-SPIKE) MIGRATING IN THE GAMMA GLOBULIN REGION" MEAN?
This specific phrase — or similar wording like "evaluation reveals a restricted band (M-spike) migrating in the gamma globulin region. If not already requested, immunofixation should be considered" — is standard LabCorp and Quest report language for a low-level M-spike finding.
What it means:
- A faint but definite monoclonal band was detected
- It is located in the gamma globulin region (where immunoglobulins migrate on electrophoresis)
- The lab is recommending immunofixation as a follow-up test to identify the antibody class (IgG, IgA, IgM, etc.) and light chain type (kappa or lambda)
What it does not mean:
- It does not mean you have cancer
- "Faint" indicates a very low level — typically < 0.5 g/dL — which is consistent with low-risk MGUS
This is one of the most common M-spike findings and in most cases results in a diagnosis of low-risk MGUS with routine annual monitoring.
DOES AN M-SPIKE MEAN CANCER?
No — the presence of an M-spike does not mean you have cancer.
The most common explanation for an M-spike is MGUS (Monoclonal Gammopathy of Undetermined Significance) — a benign, pre-malignant condition:
- MGUS affects approximately 3% of people over age 50
- Long-term studies suggest most people with MGUS never progress to myeloma
- The average risk of progression is approximately 1% per year, though this varies by M-spike level, immunoglobulin type, and serum free light chain ratio
- Individual risk is better estimated using validated scoring tools (such as the Mayo Clinic MGUS risk stratification model) than by a single percentage
Multiple myeloma is diagnosed when M-spike is combined with specific clinical criteria (CRAB features: hypercalcaemia, renal failure, anaemia, bone lesions) or myeloma-defining events. A positive M-spike alone — without these features — does not constitute a cancer diagnosis.
Other non-cancerous causes of an M-spike include:
- Chronic infections
- Autoimmune conditions
- Chronic inflammatory states
- Normal ageing (MGUS prevalence increases significantly after age 70)
WHAT IS M-SPIKE AND HOW IS IT MEASURED?
The M-spike is detected on Serum Protein Electrophoresis (SPEP) — a blood test that separates proteins in the blood by electrical charge. In a normal SPEP, proteins form a smooth, broad curve in the gamma region. When a clonal population of plasma cells produces abnormal amounts of a single immunoglobulin, a sharp, narrow peak (the "spike") appears on the electrophoresis tracing.
Important: The M-spike is not a single isolated molecule or a separate blood test ordered on its own — it is an interpreted finding derived from the SPEP result. The M-spike value (in g/dL) reflects the height and area of the monoclonal peak on the electrophoresis scan. It requires a pathologist or laboratory scientist to identify and quantify it from the tracing.
The M-spike represents M-protein (also called: monoclonal protein, paraprotein, myeloma protein, or M-component) — an abnormal immunoglobulin produced by clonal plasma cells. Unlike normal antibodies (which are diverse), M-protein is produced by a single clone of cells and is therefore identical in structure.
M-protein can be:
- A complete immunoglobulin (IgG, IgA, IgM, IgD, IgE)
- Free light chains only (kappa or lambda — detected in urine as Bence Jones protein)
- Heavy chain only (rare)
The most common M-protein types in MGUS and myeloma are IgG (most common, ~70%) and IgA (~15%).
MGUS, SMOLDERING MYELOMA, AND ACTIVE MYELOMA: THE SPECTRUM
All myeloma patients pass through earlier stages before reaching active myeloma. Understanding where an M-spike result falls on this spectrum is essential for interpreting its significance:
| Condition | M-spike level | Other criteria | Progression risk |
|---|---|---|---|
| MGUS | < 3.0 g/dL | Bone marrow plasma cells < 10%; no CRAB features | ~1% per year |
| Smoldering Multiple Myeloma (SMM) | ≥ 3.0 g/dL OR bone marrow plasma cells 10–60% | No CRAB features or myeloma-defining events | 10% per year (first 5 years) |
| Active Multiple Myeloma | Any level (or non-secretory) | CRAB features OR myeloma-defining events present | Active disease — treatment required |
CRAB features (indicators of organ damage):
- Calcium elevated (> 11 mg/dL)
- Renal dysfunction (creatinine > 2 mg/dL or CrCl < 40 mL/min)
- Anaemia (haemoglobin < 10 g/dL)
- Bone lesions (lytic lesions or osteoporosis with compression fracture)
Most people with MGUS never progress to myeloma, though risk varies by M-spike level, protein type, free light chain ratio, and duration of follow-up. MGUS also becomes increasingly common with age and is especially frequent after age 70 — so an older adult with a low, stable M-spike is in the most common scenario, not an unusual one.
MONITORING AN M-SPIKE OVER TIME
The most important principle in M-spike management is serial monitoring. The absolute level at a single time point matters less than whether the value is stable, slowly rising, or rapidly increasing.
Standard monitoring intervals:
| M-spike level | Monitoring frequency |
|---|---|
| < 0.5 g/dL (very low) | Annual SPEP + full blood count |
| 0.5–1.5 g/dL (low-moderate) | Every 6–12 months |
| 1.5–3.0 g/dL (moderate) | Every 3–6 months |
| ≥ 3.0 g/dL (high/SMM range) | Every 2–3 months initially; haematology referral |
Red flags that warrant prompt haematology referral:
- Rising M-spike (increase of ≥ 0.5 g/dL over 6 months)
- New or worsening bone pain
- Unexplained anaemia, fatigue, or weight loss
- Hypercalcaemia or renal deterioration
- New neurological symptoms
WHAT TESTS USUALLY COME NEXT AFTER AN M-SPIKE IS FOUND?
A newly detected M-spike typically triggers a structured evaluation. Standard initial workup includes:
To characterise the M-protein:
- Serum immunofixation electrophoresis (IFE) — identifies the immunoglobulin class (IgG, IgA, IgM) and light chain type (kappa or lambda)
- Serum free light chain assay — measures free kappa and lambda light chains and their ratio; an abnormal ratio is an independent risk factor for progression
To assess for organ damage (CRAB features):
- Complete blood count (CBC) — checks for anaemia
- Comprehensive metabolic panel — calcium, creatinine/eGFR (kidney function), albumin
- Quantitative immunoglobulins — IgG, IgA, IgM levels
- Beta-2 microglobulin — tumour burden marker in myeloma
- LDH — marker of cellular turnover
To evaluate bone and bone marrow (if indicated):
- Skeletal survey or whole-body low-dose CT — screening for lytic bone lesions
- Bone marrow biopsy — percentage of plasma cells; usually performed when M-spike ≥ 1.5 g/dL or when other findings suggest higher-risk disease
- Urine protein electrophoresis (UPEP) — detects Bence Jones protein (free light chains in urine)
Not all tests are ordered at initial detection — a very low M-spike (< 0.5 g/dL) in an asymptomatic individual may only require immunofixation and basic blood tests before annual monitoring begins.
INTERNAL LINKS
Related tests on HealthMatters: Abnormal Protein Band 1 · Serum Protein Electrophoresis (SPEP) · Immunoglobulin G (IgG) · Immunoglobulin A (IgA) · Immunoglobulin M (IgM) · Free Kappa Light Chains · Free Lambda Light Chains · Beta-2 Microglobulin
M-Spike
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
Frequently Asked Questions
What does an M-spike mean on a blood test?
Does an M-spike mean I have cancer?
What is a normal M-spike level?
Is 0.4 g/dL a high M-spike?
Is 0.5 g/dL a high M-spike?
What does "M-spike not observed" mean?
What does "faint restricted band (M-spike) migrating in the gamma globulin region" mean?
What is MGUS and how does it relate to M-spike?
What level of M-spike indicates multiple myeloma?
What is the difference between MGUS, smoldering myeloma, and multiple myeloma?
Can an M-spike go away or disappear?
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.
-
Prevalence of monoclonal gammopathy of undetermined significance
-
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
-
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
-
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders